Every 10-Q that 4D Molecular Therapeutics, Inc. (FDMT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FDMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FDMT filings page.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company developing AAV genetic medicines and remains pre-commercial with no product sales. For the three months ended June 30, 2026, collaboration and license revenue was $3.8 million, and for the six months it totaled $6.8 million, driven largely by its regional partnership with Otsuka for 4D-150 and its Cystic Fibrosis Foundation agreement.
The company recorded a net loss of $72.9 million in the quarter and $141.7 million year-to-date, compared with $54.7 million and $102.6 million in the prior-year periods, and its accumulated deficit reached $858.0 million. Research and development expenses for the first half of 2026 were $133.3 million, reflecting intensive clinical and preclinical activity.
As of June 30, 2026, cash, cash equivalents and marketable securities had a combined fair value of about $430.6 million, and total assets were $492.6 million. Management states these resources are sufficient to fund planned operations for at least one year. During the period, 4D Molecular Therapeutics also put in place a $200.0 million term loan facility with Hercules Capital and drew an initial $20.0 million, adding modest long-term debt to its balance sheet.
4D Molecular Therapeutics reported a larger net loss as it accelerated investment in its late-stage gene therapy pipeline for the three months ended March 31, 2026. Collaboration and license revenue rose to $3.0 million, primarily from its Otsuka partnership, while research and development spending increased to $65.0 million. The company posted a net loss of $68.8 million, compared with $48.0 million a year earlier, and ended the quarter with $457.6 million in cash, cash equivalents and marketable securities. Management believes this cash balance can fund planned operations for at least one year.
4D Molecular Therapeutics (FDMT) reported a larger quarterly loss as R&D spending increased. For the three months ended September 30, 2025, revenue was $90 thousand, research and development expense was $49.4 million, and general and administrative expense was $11.8 million, leading to a net loss of $56.9 million and a basic and diluted net loss per share of $1.01.
Liquidity remained solid with cash, cash equivalents and marketable securities totaling $372.2 million as of September 30, 2025. Net cash used in operating activities was $137.6 million for the nine months ended September 30, 2025. The company states these resources are sufficient to fund planned operations for at least one year from the financial statement issuance date.
As a subsequent event, in November 2025 FDMT completed an underwritten offering with net proceeds of approximately $93.3 million. As of November 7, 2025, shares outstanding were 57,135,075; an additional 10,513,949 shares were issuable upon exercise of pre-funded warrants at $0.0001 per share, subject to beneficial ownership limitations.
4D Molecular Therapeutics reported heavy R&D investment and widening losses for the quarter and six months ended June 30, 2025. The company held $77.2 million in cash and $339.9 million in total marketable securities (current and long-term), for total assets of $473.6 million, which management says is sufficient to fund planned operations for at least one year. Net loss was $54.7 million for the quarter and $102.6 million for the six-month period, driven by R&D expense of $47.95 million in the quarter and $88.65 million for six months. Operating cash used was $91.1 million for the six months. Accumulated deficit totaled $678.8 million and basic/diluted net loss per share was $(0.98) for the quarter and $(1.84) for six months. Subsequent events note a workforce reduction of approximately 25% with estimated cash exit costs of $3.0 million (with $0.9 million recorded).